MELISSA COUSINS: Open Payments
NPI 1396821724 · ANDERSON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$610 in 31 payments from 9 companies in 2025. Trend: 2023 $517 · 2024 $375 · 2025 $610
Food & beverage: $610
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 5 | $115 |
| ABBVIE INC. | 6 | $97 |
| Otsuka America Pharmaceutical, Inc. | 4 | $79 |
| Gilead Sciences, Inc. | 3 | $67 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
| E.R. Squibb & Sons, L.L.C. | 4 | $66 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $63 |
| Lilly USA, LLC | 2 | $40 |
| Indivior Inc. | 1 | $16 |
Products named: ARISTADA, VRAYLAR, INGREZZA, COBENFY, CAPLYTA, REXULTI, MOUNJARO, ABILIFY MAINTENA.
Industry payments across IN — which companies pay providers there.
